Yulanka Castro-Dominguez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yulanka Castro-Dominguez has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
- Carlos Mena-Hurtado
Yale School of Medicine
5 shared publications - Jun Li
University Hospitals Harrington Heart & Vascular Institute, Cleveland, Ohio
4 shared publications - Kim G. Smolderen
Yale School of Medicine
4 shared publications Gaelle Romain
Vascular Medicine Outcomes Program (VAMOS), Division of Cardiology, Department of Medicine, Yale School of Medicine, New Haven, Connecticut
3 shared publications- Mehdi H. Shishehbor
University Hospitals Harrington Heart & Vascular Institute, Cleveland, OH, USA
3 shared publications - Daniella Kadian-Dodov
Icahn School of Medicine at Mount Sinai, New York, NY, USA
2 shared publications
Latest Publications
- 1 June 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 18 (6) , e015423
Why Age Matters: Revascularization Strategy and Outcomes in Young and Elderly With CLTI
- 1 June 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 18 (6) , e015423
Why Age Matters: Revascularization Strategy and Outcomes in Young and Elderly With CLTI
- 1 May 2025
- Published by SAGE Publications in Vascular Medicine
- Vol. 30 (3) , 367-383
Research priorities for peripheral artery disease: A statement from the Society for Vascular Medicine
Lower-extremity peripheral artery disease (PAD) affects approximately 236 million people worldwide and at least eight million people in the United States (US). Despite availability of new therapies that prevent major adverse cardiovascular events (MACE), these and major adverse limb events (MALE) remain common and occur more frequently in people with PAD, either with or without coronary artery disease (CAD), compared to people with CAD who do not have PAD. The most effective therapies to prevent cardiovascular events are not identical in people with PAD and those with CAD. Walking impairment and the risk of lower-extremity amputation are significantly greater in people with PAD compared to those without PAD. This report from the Society for Vascular Medicine (SVM) proposes and summarizes high-priority topics for scientific investigation in PAD, with the goal of improving health outcomes in people with PAD. To develop this report, a multidisciplinary team of scientists and clinicians reviewed literature, proposed high-priority topics for scientific investigation, and voted to rank the highest priority topics for scientific investigation. Priorities for clinical scientific investigation include: determine the current prevalence of PAD in the US by age, sex, race, and ethnicity; improve methods to diagnose PAD; develop new medical therapies to eliminate walking impairment; and improve implementation of established therapies to reduce rates of MACE and MALE in people with PAD. Priorities in basic science and translational science investigation include: developing animal models that closely resemble the vascular, skeletal muscle, and platelet pathology in patients with PAD and defining the genetic and epigenetic contributors to PAD and PAD-associated outcomes. Successful investigation of these research priorities will require more well-trained investigators focused on scientific investigation of PAD, greater and more efficient enrollment of diverse patients with PAD in randomized clinical trials, and increased research funding dedicated to PAD.
- 1 May 2025
- Published by SAGE Publications in Vascular Medicine
- Vol. 30 (3) , 367-383
Research priorities for peripheral artery disease: A statement from the Society for Vascular Medicine
Lower-extremity peripheral artery disease (PAD) affects approximately 236 million people worldwide and at least eight million people in the United States (US). Despite availability of new therapies that prevent major adverse cardiovascular events (MACE), these and major adverse limb events (MALE) remain common and occur more frequently in people with PAD, either with or without coronary artery disease (CAD), compared to people with CAD who do not have PAD. The most effective therapies to prevent cardiovascular events are not identical in people with PAD and those with CAD. Walking impairment and the risk of lower-extremity amputation are significantly greater in people with PAD compared to those without PAD. This report from the Society for Vascular Medicine (SVM) proposes and summarizes high-priority topics for scientific investigation in PAD, with the goal of improving health outcomes in people with PAD. To develop this report, a multidisciplinary team of scientists and clinicians reviewed literature, proposed high-priority topics for scientific investigation, and voted to rank the highest priority topics for scientific investigation. Priorities for clinical scientific investigation include: determine the current prevalence of PAD in the US by age, sex, race, and ethnicity; improve methods to diagnose PAD; develop new medical therapies to eliminate walking impairment; and improve implementation of established therapies to reduce rates of MACE and MALE in people with PAD. Priorities in basic science and translational science investigation include: developing animal models that closely resemble the vascular, skeletal muscle, and platelet pathology in patients with PAD and defining the genetic and epigenetic contributors to PAD and PAD-associated outcomes. Successful investigation of these research priorities will require more well-trained investigators focused on scientific investigation of PAD, greater and more efficient enrollment of diverse patients with PAD in randomized clinical trials, and increased research funding dedicated to PAD.
- 24 January 2025
- Published by Elsevier in Interventional Cardiology Clinics
- Vol. 14 (2) , 297-310
Iliofemoral Acute Deep Venous Thrombosis, Chronic Deep Venous Thrombosis, and May-Thurner Syndrome
- 24 January 2025
- Published by Elsevier in Interventional Cardiology Clinics
- Vol. 14 (2) , 297-310
Iliofemoral Acute Deep Venous Thrombosis, Chronic Deep Venous Thrombosis, and May-Thurner Syndrome
- 23 August 2024
- Published by SAGE Publications in Vascular Medicine
- Vol. 29 (5) , 612-615
Executive Summary of Standard Operating Procedures for Society for Vascular Medicine (SVM) publications
- 23 August 2024
- Published by SAGE Publications in Vascular Medicine
- Vol. 29 (5) , 612-615
Executive Summary of Standard Operating Procedures for Society for Vascular Medicine (SVM) publications
- Open Access
- 16 October 2023
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 2 (6) , 101107
Prospective, Multicenter Registry to Assess Safety and Efficacy of Radial Access for Peripheral Artery Interventions
- 16 October 2023
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 2 (6) , 101107
Open AccessProspective, Multicenter Registry to Assess Safety and Efficacy of Radial Access for Peripheral Artery Interventions
- 27 June 2023
- Published by Elsevier in The American Journal of Cardiology
- Vol. 201, 166-169
Representativeness of Peripheral Artery Disease Randomized Clinical Trials Supporting Current Guidelines
- 27 June 2023
- Published by Elsevier in The American Journal of Cardiology
- Vol. 201, 166-169
Representativeness of Peripheral Artery Disease Randomized Clinical Trials Supporting Current Guidelines
- 9 June 2023
- Published by SAGE Publications in Vascular Medicine
- Vol. 28 (3) , 179-181
The problem of disparities in vascular health
- 9 June 2023
- Published by SAGE Publications in Vascular Medicine
- Vol. 28 (3) , 179-181
The problem of disparities in vascular health
- 30 May 2023
- Published by SAGE Publications in Vascular Medicine
- Vol. 28 (5) , 387-396
Immunologic profiles in patients with chronic limb-threatening ischemia undergoing endovascular revascularization
Background: Inflammation and immune dysregulation have been associated with adverse outcomes in cardiovascular disease. There is limited understanding of the association of different profiles of white blood cell (WBC) subsets and red cell distribution width (RDW) in patients with chronic limb-threatening ischemia (CLTI). Methods: Patients with CLTI undergoing endovascular revascularization in our single-center, tertiary care hospital from 2017 to 2019, who had a preceding complete blood count (CBC) with WBC differentials ( n =213), were included in the analysis. Patient characteristics, laboratory values, and clinical outcomes were collected. Cox proportional hazards regression models were used to assess for associations between all-cause mortality and leukocyte subset; multivariate analysis was used to account for confounders. Kaplan–Meier curves were generated to depict survival censored at 1 year postrevascularization using baseline CBC indices. Results: Adjusting for confounders, elevated RDW was associated with increased mortality (continuous per % increase, adjusted hazard ratio [HR] 1.33, p < 0.001). Baseline lymphopenia was associated with mortality in univariate analysis. Other leukocyte subtypes were not associated with mortality outcomes in our population. Exploratory analysis showed negative deflections in ∆WBC from pre- to postprocedure day 1 were affiliated with increased mortality when adjusted for age, sex, race, chronic kidney disease, and baseline hemoglobin (∆WBC HR 1.16, p = 0.004). Further exploratory analysis showed an association between RDW and all-comers readmission. Conclusions: The utilization of a periprocedural WBC subset differential can be a useful adjunct to risk-stratify patients with CLTI undergoing endovascular revascularization. Further studies are needed to understand potential ways to modulate immune dysregulation so as to improve mortality outcomes.
- 30 May 2023
- Published by SAGE Publications in Vascular Medicine
- Vol. 28 (5) , 387-396
Immunologic profiles in patients with chronic limb-threatening ischemia undergoing endovascular revascularization
Background: Inflammation and immune dysregulation have been associated with adverse outcomes in cardiovascular disease. There is limited understanding of the association of different profiles of white blood cell (WBC) subsets and red cell distribution width (RDW) in patients with chronic limb-threatening ischemia (CLTI). Methods: Patients with CLTI undergoing endovascular revascularization in our single-center, tertiary care hospital from 2017 to 2019, who had a preceding complete blood count (CBC) with WBC differentials ( n =213), were included in the analysis. Patient characteristics, laboratory values, and clinical outcomes were collected. Cox proportional hazards regression models were used to assess for associations between all-cause mortality and leukocyte subset; multivariate analysis was used to account for confounders. Kaplan–Meier curves were generated to depict survival censored at 1 year postrevascularization using baseline CBC indices. Results: Adjusting for confounders, elevated RDW was associated with increased mortality (continuous per % increase, adjusted hazard ratio [HR] 1.33, p < 0.001). Baseline lymphopenia was associated with mortality in univariate analysis. Other leukocyte subtypes were not associated with mortality outcomes in our population. Exploratory analysis showed negative deflections in ∆WBC from pre- to postprocedure day 1 were affiliated with increased mortality when adjusted for age, sex, race, chronic kidney disease, and baseline hemoglobin (∆WBC HR 1.16, p = 0.004). Further exploratory analysis showed an association between RDW and all-comers readmission. Conclusions: The utilization of a periprocedural WBC subset differential can be a useful adjunct to risk-stratify patients with CLTI undergoing endovascular revascularization. Further studies are needed to understand potential ways to modulate immune dysregulation so as to improve mortality outcomes.
- 29 January 2023
- Published by SAGE Publications in Vascular Medicine
- Vol. 28 (2) , 150-152
Use of drug-coated balloons and stents in patients with femoropopliteal artery disease and severe chronic kidney disease
- 29 January 2023
- Published by SAGE Publications in Vascular Medicine
- Vol. 28 (2) , 150-152
Use of drug-coated balloons and stents in patients with femoropopliteal artery disease and severe chronic kidney disease